Efficacy of Hydroxychloroquine in Rheumatic Diseases and Associated Co- morbidities

Document Type : Original Article

Authors

physical medicine, rheumatology and rehabilitation departement, faculty of medicine , assiut university

Abstract

Background In the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), the antimalarial drug hydroxychloroquine (HCQ) is frequently used. It reduces the risk of illness flare-ups, prevents thrombosis, and lowers the possibility of long-term organ damage. HCQ's advantageous impact on cholesterol levels and diabetes risk reduction.
Objective: The aim of the present study was to identify the efficacy of HCQ in rheumatic diseases and associated comorbidities.
Patients and method: This cross-sectional study included a total of 71 RA and 9 SLE patients, attending at Department of Rheumatology, Rehabilitation and Physical Medicine, Assiut University Hospitals. University Hospitals. All patients subjected to complete history taking including medication history [HCQ dose (daily, cumulative) and duration], clinical examination, disease activity of RA was defined by DAS 28 (Disease activity scale) and disease activity of SLE by SELDAI-2K (Systemic Lupus Erythematosus Disease Activity Index). Laboratory assessments were performed including: routine investigation, autoantibodies
Results: HCQ has a role in control diabetes mellitus (DM) of our diabetic patients and had role in reducing the risk for atherosclerosis and a significant reduction in the lipid profiles as well as AI has been observed.
Conclusion: It could be concluded that HCQ is associated with a reduced risk of rheumatic diseases and its associated comorbidities.
 

Keywords

The Egyptian Journal of Hospital Medicine
Volume 89, Issue 2
October 2022
Pages 6986-6992

Files

Share

How to cite

Statistics